专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014125164A1 A METHOD FOR DETERMINING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) RELATED BIOMARKERS, A METHOD TO MONITOR THE DEVELOPMENT AND TREATMENT OF ARDS IN A PATIENT 审中-公开
标题翻译：用于确定急性呼吸道综合征（ARDS）相关生物标志物的方法，监测患者中ARDS发展和治疗的方法
公开(公告)号：WO2014125164A1
公开(公告)日：2014-08-21
申请号：PCT/FI2014/050051
申请日：2014-01-22
申请人： FARON PHARMACEUTICALS OY , MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
发明人： MAKSIMOW, Mikael , SALMI, Marko , JALKANEN, Markku , JALKANEN, Sirpa
IPC分类号： G01N33/573 , G01N30/90 , C07K14/705 , C07K14/565 , C12N9/16
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
摘要翻译：本发明涉及监测患者ARDS发展和治疗ARDS的方法。用于监测ARDS发展的方法是基于将在稍后时间点绘制的样品中获得的生物标志物的水平或活性与在先前时间点绘制的样品中相同生物标志物的水平或活性进行比较。某种生物标志物的水平或活性的有利变化表示疾病的消退（患者的恢复），相反地，某种生物标志物的水平或活性的不利变化代表疾病的恶化。例如，如果所监测的一种或多种生物标志物的水平或活性停止显示有利的变化或开始显示不利的变化，则通过施用可用于治疗ARDS的治疗活性剂来增强患者的治疗。本发明还涉及用于同时测定来自患者的样品中多个生物标志物的方法，其中所述生物标志物与ARDS相关。确定生物标志物的水平或活性。本发明还涉及可用于实施该方法的诊断试剂盒，特别是包含芯片的试剂盒，例如适用于生物芯片技术的微阵列。

2. 发明申请

WO2009053523A1 A NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES 审中-公开
标题翻译：用于监测疾病发展和评估治疗效果的新生物标志物
公开(公告)号：WO2009053523A1
公开(公告)日：2009-04-30
申请号：PCT/FI2008/050576
申请日：2008-10-15
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： G01N33/573 , C07K14/705 , C12N9/16 , G01N33/574
CPC分类号： G01N33/57484 , G01N2333/70596 , G01N2800/245 , G01N2800/324 , G01N2800/56
摘要： The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.
摘要翻译：本发明涉及用于监测患者疾病发展或用于评估患者中的细胞因子疗法或他汀类药物治疗的功效的方法，其中从所述患者抽取的组织液中的CD73用作生物标志物。本发明还涉及从个体组织液中抽出的样品中测定CD73蛋白的方法。

3. 发明申请

WO2008025870A1 COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME 审中-公开
标题翻译：组合物特别适用于治疗或预防代谢综合征
公开(公告)号：WO2008025870A1
公开(公告)日：2008-03-06
申请号：PCT/FI2007/000206
申请日：2007-08-22
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： A61K31/51 , A61K31/675 , A61K31/427 , A23L1/302 , C07D277/24 , A61P3/00 , A61P9/10
CPC分类号： C07D277/24 , A23L33/15 , A23V2002/00 , A61K31/426 , A61K31/51 , A61K31/675 , A23V2250/7042
摘要： This invention concerns the use of vitamin B1, vitamin B1 derivatives or vitamin B1 precursors as inhibitors of semicarbazide-sensitive amine oxidases (SSAO) in non-diabetic individuals, in particular for use in treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom. Furthermore, the invention concerns food products or food additives comprising an amine oxidase enzyme inhibitor which is a vitamin B1 derivative or vitamin B1 precursor. The invention concerns also novel vitamin B1 derivatives and their use.
摘要翻译：本发明涉及维生素B1，维生素B1衍生物或维生素B1前体作为非糖尿病个体中氨基脲敏感性胺氧化酶（SSAO）的抑制剂，特别是用于治疗或预防代谢综合征及由此产生的疾病或病症。此外，本发明涉及包含作为维生素B1衍生物或维生素B1前体的胺氧化酶抑制剂的食品或食品添加剂。本发明还涉及维生素B1衍生物及其用途。

4. 发明申请

WO2005072738A1 COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME 审中-公开
标题翻译：组合物特别适用于治疗或预防代谢综合征
公开(公告)号：WO2005072738A1
公开(公告)日：2005-08-11
申请号：PCT/FI2005/000035
申请日：2005-01-19
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： A61K31/51
CPC分类号： A61K31/51 , A23L33/15 , A23V2002/00 , A23V2200/328 , A23V2250/7042 , A23V2200/3262 , A23V2200/332
摘要： This invention concerns the use of an amine oxidase enzyme inhibitor for the manufacture of a pharmaceutical preparation useful in the treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom. The invention concerns also the use of vitamin B1 or a metabolite thereof for the manufacture of a pharmaceutical preparation useful as an amine oxidase enzyme inhibitor. Furthermore, the invention concerns a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
摘要翻译：本发明涉及胺氧化酶抑制剂在制备可用于治疗或预防代谢综合征和由此产生的疾病或病症的药物制剂中的用途。本发明还涉及使用维生素B1或其代谢物来制造可用作胺氧化酶抑制剂的药物制剂。此外，本发明涉及包含与食品组合的胺氧化酶抑制剂的食品，包含胺氧化酶抑制剂与液体，固体或半固体载体组合的食品添加剂。

5. 发明申请

WO2010122217A1 A NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON 审中-公开
标题翻译：基于此的新型细胞和治疗与诊断方法
公开(公告)号：WO2010122217A1
公开(公告)日：2010-10-28
申请号：PCT/FI2010/050266
申请日：2010-04-06
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： C07K14/05 , A61K39/395 , A61P35/00
CPC分类号： C12N15/1138 , A61K31/58 , A61K35/15 , A61K38/17 , A61K38/202 , A61K38/2026 , A61K2039/505 , C07K16/28 , C12N15/115 , C12Q1/6883 , C12Q1/6886
摘要： The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.
摘要翻译：本发明涉及一种衍生自人体的新型细胞，其中所述细胞包含Clever-1受体; 涉及一种影响个体的免疫系统和用于治疗与免疫系统的功能有关的疾病或病症的方法，以及用于筛选可能对抗Clever-1疗法或诊断的癌症患者的方法怀孕并发症或估计孕妇出现并发症的风险。

6. 发明申请

WO2005063261A1 AMINOGLYCOSIDE ANTIBIOTICS FOR USE AS VAP-1/SSAO INHIBITORS 审中-公开
标题翻译：用作VAP-1 / SSAO抑制剂的氨基丁糖抗体
公开(公告)号：WO2005063261A1
公开(公告)日：2005-07-14
申请号：PCT/FI2004/000772
申请日：2004-12-17
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
发明人： JALKANEN, Sirpa , SALMI, Marko , JALKANEN, Markku
IPC分类号： A61K31/702
CPC分类号： A61K31/7048 , A61K31/7034
摘要： The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.
摘要翻译：本发明涉及包含一个或多个糖部分的化合物（其任选为氨基化合物）以及可能的其它部分的用途，其中所述化合物是包含至少两个氨基取代基的分子，所述氨基取代基是伯，仲或叔氨基，其中所述氨基取代基连接到一个单个糖部分或连接到该分子的几个糖部分或其它部分，或连接到分子的两个部分或连接于链的取代基的链，用于制备可用作药剂的药物制剂影响胺氧化酶活性，更特别地抑制VAP-1 / SSAO活性。优选的化合物是氨基糖苷类抗生素，例如链霉素，净霉素，遗传霉素，庆大霉素，嘌呤霉素，妥布霉素和阿米卡星。待治疗的优选条件是炎性疾病或病症，与碳水化合物代谢有关的疾病，与脂肪细胞分化或功能或平滑肌细胞功能异常有关的疾病和血管疾病。

7. 发明申请

WO2006134203A1 COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS 审中-公开
标题翻译：用于治疗或预防胺氧化酶相关疾病或病症的化合物
公开(公告)号：WO2006134203A1
公开(公告)日：2006-12-21
申请号：PCT/FI2006/000188
申请日：2006-06-12
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , JALKANEN, Markku , SALMI, Marko
发明人： JALKANEN, Sirpa , JALKANEN, Markku , SALMI, Marko
IPC分类号： A61K31/7088 , C12N15/11 , C07H21/02 , C12N9/06
CPC分类号： C12N15/1138 , C12N2310/14 , C12Y104/03021
摘要： This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.
摘要翻译：本发明涉及下调调节血管粘附蛋白1（VAP-1）在预防或治疗受益于VAP-1的抑制或下调的疾病或病症中的表达的小干扰RNA（siRNA）。还包括包含所述siRNA与药学上可接受的载体组合的药物组合物。此外，本发明涉及包含编码所述双链体的siRNA双链体或反义链的核酸的表达载体，其允许所述siRNA双链体或反义链在哺乳动物细胞内表达。还包括包含所述表达载体与药学上可接受的载体组合的药物组合物。

8. 发明申请

WO2006128951A1 COMPOSITIONS FOR TARGETING AMINE OXIDASES IN VIVO 审中-公开
标题翻译：用于在体液中靶向氨氧化物的组合物
公开(公告)号：WO2006128951A1
公开(公告)日：2006-12-07
申请号：PCT/FI2006/000144
申请日：2006-05-04
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa , SALMI, Marko
发明人： JALKANEN, Sirpa , SALMI, Marko
IPC分类号： C07K7/06 , A61K38/08 , A61K47/00 , C12N9/02
CPC分类号： C07K7/06 , A61K38/08 , A61K47/64
摘要： This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising a peptide having the capability to bind to said enzyme, wherein said peptide further is conjugated to a therapeutically active agent. Still further, the invention concerns a novel peptide and its uses, especially as VAP-1 inhibitor.
摘要翻译：本发明涉及用于在体内靶向胺氧化酶的诊断组合物，所述组合物包含具有结合所述酶的能力的标记肽。此外，本发明涉及用于调节胺氧化酶的活性的药物组合物，所述组合物包含具有结合所述酶的能力的肽，其中所述肽进一步与治疗活性剂缀合。此外，本发明涉及新型肽及其用途，特别是作为VAP-1抑制剂。

9. 发明申请

WO2007042602A1 METHOD FOR TREATING OR PREVENTING ISCHEMIA REPERFUSION INJURY OR MULTI-ORGAN FAILURE 审中-公开
标题翻译：治疗或预防ISCHEMIA REPERFUSION INJURY或多器官功能障碍的方法
公开(公告)号：WO2007042602A1
公开(公告)日：2007-04-19
申请号：PCT/FI2006/000308
申请日：2006-09-22
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa
发明人： JALKANEN, Sirpa
IPC分类号： A61K38/21 , C07K14/565 , A61P29/00
CPC分类号： C07K14/565 , A61K38/215 , A61K2300/00
摘要： This invention concerns the use of a therapeutically active agent for the manufacture of a pharmaceutical preparation useful in a method for prevention or treatment of ischemia reperfusion injury or multi-organ failure in an individual. According to the invention, said agent is plain interferon beta and said agent is intended for use without simultaneous administration of one or more agent affecting the adenosine level in individual.
摘要翻译：本发明涉及治疗活性剂在制备可用于预防或治疗个体缺血再灌注损伤或多器官功能衰竭的方法中的药物制剂的用途。根据本发明，所述试剂是纯的干扰素β，并且所述试剂用于在不同时施用影响个体中腺苷水平的一种或多种试剂的情况下使用。

10. 发明申请

WO2004084933A1 ELEVATION OF ADENOSINE LEVEL BY CYTOKINE-INDUCED EXPRESSION OF CD73 审中-公开
标题翻译： CD73细胞因子诱导表达对腺苷水平的升高
公开(公告)号：WO2004084933A1
公开(公告)日：2004-10-07
申请号：PCT/FI2004/000158
申请日：2004-03-19
申请人： FARON PHARMACEUTICALS OY , JALKANEN, Sirpa
发明人： JALKANEN, Sirpa
IPC分类号： A61K38/19
CPC分类号： A61K38/20 , A61K31/7076 , A61K38/177 , A61K38/21
摘要： This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression, or a combination thereof. Furthermore, the invention concerns a method for prevention or treatment of a disease or disorder requiring or benefiting from the elevation of the adenosine level in an individual, such as inflammatory conditions. Furthermore, the invention concerns a method of up-regulating endothelial CD73 expression in an individual by administering to said individual an effective amount of a cytokine or another factor being capable of inducing endothelial CD73 expression, and to a method for prevention or treatment of a disease or disorder requiring or benefiting from up-regulating endothelial CD73 expression.
摘要翻译：本发明涉及一种通过向所述个体施用有效量的i）重组蛋白CD73或ii）细胞因子或能够诱导内皮CD73表达的另一因子或组合的方法来诱导个体中腺苷升高的方法它们。此外，本发明涉及一种预防或治疗需要或有益于个体中腺苷水平升高的疾病或病症的方法，例如炎性病症。此外，本发明涉及一种通过向所述个体施用有效量的细胞因子或能够诱导内皮CD73表达的另一因素，以及预防或治疗疾病的方法来上调个体内皮CD73表达的方法或需要或受益于上调内皮CD73表达的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式